(Q51853893)

English

A double-blind, randomized, placebo-controlled, parallel-group study of Sativex, in subjects with symptoms of spasticity due to multiple sclerosis.

scientific article published on 19 March 2010

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

14 April 2018

http://europepmc.org/abstract/MED/20307378

A double-blind, randomized, placebo-controlled, parallel-group study of Sativex, in subjects with symptoms of spasticity due to multiple sclerosis. (English)

1 reference

Europe PubMed Central

PubMed publication ID

14 April 2018

http://europepmc.org/abstract/MED/20307378

multiple sclerosis

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

2

1 reference

Europe PubMed Central

PubMed publication ID

14 April 2018

http://europepmc.org/abstract/MED/20307378

author name string

C Collin

1

1 reference

Europe PubMed Central

PubMed publication ID

14 April 2018

http://europepmc.org/abstract/MED/20307378

G Waberzinek

3

1 reference

Europe PubMed Central

PubMed publication ID

14 April 2018

http://europepmc.org/abstract/MED/20307378

Z Alsindi

4

1 reference

Europe PubMed Central

PubMed publication ID

14 April 2018

http://europepmc.org/abstract/MED/20307378

P Davies

5

1 reference

Europe PubMed Central

PubMed publication ID

14 April 2018

http://europepmc.org/abstract/MED/20307378

K Powell

6

1 reference

Europe PubMed Central

PubMed publication ID

14 April 2018

http://europepmc.org/abstract/MED/20307378

W Notcutt

7

1 reference

Europe PubMed Central

PubMed publication ID

14 April 2018

http://europepmc.org/abstract/MED/20307378

C O'Leary

8

1 reference

Europe PubMed Central

PubMed publication ID

14 April 2018

http://europepmc.org/abstract/MED/20307378

S Ratcliffe

9

1 reference

Europe PubMed Central

PubMed publication ID

14 April 2018

http://europepmc.org/abstract/MED/20307378

I Nováková

10

1 reference

Europe PubMed Central

PubMed publication ID

14 April 2018

http://europepmc.org/abstract/MED/20307378

O Zapletalova

11

1 reference

Europe PubMed Central

PubMed publication ID

14 April 2018

http://europepmc.org/abstract/MED/20307378

J Piková

12

1 reference

Europe PubMed Central

PubMed publication ID

14 April 2018

http://europepmc.org/abstract/MED/20307378

Z Ambler

13

1 reference

Europe PubMed Central

PubMed publication ID

14 April 2018

http://europepmc.org/abstract/MED/20307378

publication date

19 March 2010

1 reference

Europe PubMed Central

PubMed publication ID

14 April 2018

http://europepmc.org/abstract/MED/20307378

Neurological Research

1 reference

Europe PubMed Central

PubMed publication ID

14 April 2018

http://europepmc.org/abstract/MED/20307378

32

1 reference

Europe PubMed Central

PubMed publication ID

14 April 2018

http://europepmc.org/abstract/MED/20307378

5

1 reference

Europe PubMed Central

PubMed publication ID

14 April 2018

http://europepmc.org/abstract/MED/20307378

451-459

1 reference

Europe PubMed Central

PubMed publication ID

14 April 2018

http://europepmc.org/abstract/MED/20307378

Prevalence and treatment of spasticity reported by multiple sclerosis patients

1 reference

https://api.crossref.org/works/10.1179%2F016164109X12590518685660

21 January 2018

Regional variations in the prevalence of multiple sclerosis in French farmers

1 reference

https://api.crossref.org/works/10.1179%2F016164109X12590518685660

21 January 2018

High-dose oral baclofen: experience in patients with multiple sclerosis

1 reference

https://api.crossref.org/works/10.1179%2F016164109X12590518685660

21 January 2018

Pharmacology of cannabinoid CB1 and CB2 receptors.

1 reference

https://api.crossref.org/works/10.1179%2F016164109X12590518685660

21 January 2018

Neuropharmacology and therapeutic potential of cannabinoids

1 reference

https://api.crossref.org/works/10.1179%2F016164109X12590518685660

21 January 2018

A tale of two cannabinoids: the therapeutic rationale for combining tetrahydrocannabinol and cannabidiol

1 reference

https://api.crossref.org/works/10.1179%2F016164109X12590518685660

21 January 2018

Randomized controlled trial of cannabis-based medicine in spasticity caused by multiple sclerosis

1 reference

https://api.crossref.org/works/10.1179%2F016164109X12590518685660

21 January 2018

Validity, reliability, and clinical importance of change in a 0-10 numeric rating scale measure of spasticity: a post hoc analysis of a randomized, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1179%2F016164109X12590518685660

21 January 2018

The Barthel ADL Index: a reliability study

1 reference

https://api.crossref.org/works/10.1179%2F016164109X12590518685660

21 January 2018

A review of the properties and limitations of the Ashworth and modified Ashworth Scales as measures of spasticity.

1 reference

https://api.crossref.org/works/10.1179%2F016164109X12590518685660

21 January 2018

EuroQol--a new facility for the measurement of health-related quality of life

1 reference

https://api.crossref.org/works/10.1179%2F016164109X12590518685660

21 January 2018

EuroQol: the current state of play

1 reference

https://api.crossref.org/works/10.1179%2F016164109X12590518685660

21 January 2018

A health-related quality of life measure for multiple sclerosis

1 reference

https://api.crossref.org/works/10.1179%2F016164109X12590518685660

21 January 2018

What is meant by intention to treat analysis? Survey of published randomised controlled trials

1 reference

https://api.crossref.org/works/10.1179%2F016164109X12590518685660

21 January 2018

Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)

1 reference

https://api.crossref.org/works/10.1179%2F016164109X12590518685660

21 January 2018

Cannabinoids control spasticity and tremor in a multiple sclerosis model

1 reference

https://api.crossref.org/works/10.1179%2F016164109X12590518685660

21 January 2018

Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1179%2F016164109X12590518685660

21 January 2018

Cannabinoids in multiple sclerosis (CAMS) study: safety and efficacy data for 12 months follow up.

1 reference

https://api.crossref.org/works/10.1179%2F016164109X12590518685660

21 January 2018

A preliminary controlled study to determine whether whole-plant cannabis extracts can improve intractable neurogenic symptoms

1 reference

https://api.crossref.org/works/10.1179%2F016164109X12590518685660

21 January 2018

Long-term use of a cannabis-based medicine in the treatment of spasticity and other symptoms in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1179%2F016164109X12590518685660

21 January 2018

Efficacy, safety and tolerability of an orally administered cannabis extract in the treatment of spasticity in patients with multiple sclerosis: a randomized, double-blind, placebo-controlled, crossover study

1 reference

https://api.crossref.org/works/10.1179%2F016164109X12590518685660

21 January 2018

Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1179%2F016164109X12590518685660

21 January 2018

Efficacy of two cannabis based medicinal extracts for relief of central neuropathic pain from brachial plexus avulsion: results of a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1179%2F016164109X12590518685660

21 January 2018

Oromucosal delta9-tetrahydrocannabinol/cannabidiol for neuropathic pain associated with multiple sclerosis: an uncontrolled, open-label, 2-year extension trial

1 reference

https://api.crossref.org/works/10.1179%2F016164109X12590518685660

21 January 2018

Sativex successfully treats neuropathic pain characterised by allodynia: a randomised, double-blind, placebo-controlled clinical trial

1 reference

https://api.crossref.org/works/10.1179%2F016164109X12590518685660

21 January 2018

Identifiers

10.1179/016164109X12590518685660

1 reference

Europe PubMed Central

PubMed publication ID

14 April 2018

http://europepmc.org/abstract/MED/20307378

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

14 April 2018

http://europepmc.org/abstract/MED/20307378

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q51853893&oldid=2133737234"